Effect of Anti-Obesity Drug on Cardiovascular Risk Factors: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
Open accessThe DOI matches its Crossref record; 56 of the 57 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Anti-obesity drugs are widely used to prevent the complications of obesity, however, the effects of anti-obesity drugs on cardiovascular risk factors are unclear at the present time. We carried out a comprehensively systematic review and meta-analysis to assess the effects of anti-obesity drugs on cardiovascular risk factors. METHODOLOGY AND PRINCIPAL FINDINGS: We systematically searched Medline, EmBase, the Cochrane Central Register of Controlled Trials, reference lists of articles and proceedings of major meetings for relevant literatures. We included randomized placebo-controlled trials that reported the effects of anti-obesity drugs on cardiovascular risk factors compared to placebo. Overall, orlistat produced a reduction of 2.39 kg (95%CI-3.34 to -1.45) for weight, a reduction of 0.27 mmol/L (95%CI: -0.36 to -0.17) for total cholesterol, a reduction of 0.21 mmol/L (95%CI: -0.30 to -0.12) for LDL, a reduction of 0.12 mmol/L (95%CI: -0.20 to -0.04) for fasting glucose, 1.85 mmHg reduction (95%CI: -3.30 to -0.40) for SBP, and a reduction of 1.49 mmHg (95%CI: -2.39 to -0.58) for DBP. Sibutramine only showed effects on weight loss and triglycerides reduction with statistical significances. Rimonabant was associated with statistically significant effects on weight loss, SBP reduction and DBP reduction. No other significantly different effects were identified between anti-obesity therapy and placebo. CONCLUSION/SIGNIFICANCE: We identified that anti-obesity therapy was associated with a decrease of weight regardless of the type of the drug. Orlistat and rimonabant could lead to an improvement on cardiovascular risk factors. However, Sibutramine may have a direct effect on cardiovascular risk factors.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures




Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“A recent meta-analysis concerning anti-obesity drugs reported a mean weight loss of 3.13 kg, but marked improvements in dyslipidemia were absent [134].”
From Dyslipidemia in obesity: Mechanisms and potential targets (2013) · cites this paper as [134]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Preferred Reporting Items for Systematic Reviews and Meta-Analyses: the PRISMA statement
Moher, D., Liberati, A., Tetzlaff, J., Altman, D. G., & for the PRISMA Group (2009) · BMJ · doi:10.1136/bmj.b2535 · Cited by 83,823
Preferred reporting items for systematic reviews and meta-analyses: the PRISMA Statement.
(2009) · PubMed Central · Cited by 44,859
Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement
Moher, D., Liberati, A., Tetzlaff, J., Altman, D. G., & the PRISMA Group* (2009) · Annals of Internal Medicine · doi:10.7326/0003-4819-151-4-200908180-00135 · Cited by 37,554
Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement
Moher, D., Liberati, A., Tetzlaff, J., & Altman, D. G. (2009) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2009.06.005 · Cited by 19,575
Assessing the quality of reports of randomized clinical trials: Is blinding necessary?
Jadad, A. R., Moore, R. A., Carroll, D., Jenkinson, C., Reynolds, D. J. M., Gavaghan, D. J., & McQuay, H. J. (1996) · Controlled Clinical Trials · doi:10.1016/0197-2456(95)00134-4 · Cited by 17,582
Zhang, Q., Wang, C., Zheng, M., Li, Y., Li, J., Zhang, L., Shang, X., & Yan, C. (2015) · Cerebrovascular Diseases · doi:10.1159/000369778 · Cited by 11,533
Dong, Y., Hao, L., Shi, Z., Wang, G., Zhang, Z., & Han, C. (2013) · Urologia Internationalis · doi:10.1159/000351405 · Cited by 4,540
Hubert, H. B., Feinleib, M., McNamara, P. M., & Castelli, W. P. (1983) · Circulation · doi:10.1161/01.cir.67.5.968 · Cited by 4,241
The Continuing Epidemics of Obesity and Diabetes in the United States
Mokdad, A. H. (2001) · JAMA · doi:10.1001/jama.286.10.1195 · Cited by 2,730
Fuller, N. R., Colagiuri, S., Schofield, D., Olson, A. D., Shrestha, R., Holzapfel, C., Wolfenstetter, S. B., Holle, R., Ahern, A. L., Hauner, H., et al. (2013) · International Journal of Obesity · doi:10.1038/ijo.2012.139 · Cited by 2,117
Cited by
Dyslipidemia in obesity: Mechanisms and potential targets
Klop, B., Elte, J., & Cabezas, M. (2013) · Nutrients · doi:10.3390/nu5041218 · Cited by 1,665
“13 mmol/L reduction in TG, whereas rimonabant did not show any lipid improvements [134].”
BackgroundAnti-obesity drug discovery: advances and challenges
Müller, T. D., Blüher, M., Tschöp, M. H., & DiMarchi, R. D. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00337-8 · Cited by 1,021
Long-term Drug Treatment for Obesity: A Systematic and Clinical Review
Yanovski, S. Z., & Yanovski, J. A. (2014) · JAMA · doi:10.1001/jama.2013.281361 · Cited by 876
Obesity, adiposity, and dyslipidemia: a consensus statement from the National Lipid Association
Bays, H. E., Toth, P. P., Kris-Etherton, P. M., Abate, N., Aronne, L. J., Brown, W. V., Gonzalez-Campoy, J. M., Jones, S. R., Kumar, R., La Forge, R., et al. (2013) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2013.04.001 · Cited by 521
“Nonetheless, even among older and withdrawn weight management drugs, the potential of such agents in improving health was supported by improvements in lipid levels, as well as improvement in other metabolic parameters.(253) The rimonobant development program is illustrative of both the promise and the challenges in ch…”
BackgroundDrugs Commonly Associated With Weight Change: A Systematic Review and Meta-analysis
Domecq, J. P., Prutsky, G., Leppin, A., Sonbol, M. B., Altayar, O., Undavalli, C., Wang, Z., Elraiyah, T., Brito, J. P., Mauck, K. F., et al. (2015) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2014-3421 · Cited by 334
Comprehensive review of cardiovascular toxicity of drugs and related agents
Mladěnka, P., Applová, L., Patočka, J., Costa, V. M., Remiao, F., Pourová, J., Mladěnka, A., Karlíčková, J., Jahodář, L., Vopršalová, M., et al. (2018) · Medicinal Research Reviews · doi:10.1002/med.21476 · Cited by 310
Expert panel report: Guidelines (2013) for the management of overweight and obesity in adults
(2014) · Obesity · doi:10.1002/oby.20660 · Cited by 257
Defining Weight Loss After Bariatric Surgery: a Call for Standardization
Grover, B. T., Morell, M. C., Kothari, S. N., Borgert, A. J., Kallies, K. J., & Baker, M. T. (2019) · Obesity Surgery · doi:10.1007/s11695-019-04022-z · Cited by 192
Total Weight Loss as the Outcome Measure of Choice After Roux-en-Y Gastric Bypass
Corcelles, R., Boules, M., Froylich, D., Hag, A., Daigle, C. R., Aminian, A., Brethauer, S. A., Burguera, B., & Schauer, P. R. (2016) · Obesity Surgery · doi:10.1007/s11695-015-2022-y · Cited by 170
Canagliflozin: effects in overweight and obese subjects without diabetes mellitus
Bays, H. E., Weinstein, R., Law, G., & Canovatchel, W. (2014) · Obesity · doi:10.1002/oby.20663 · Cited by 166
“1) FPG status, n (%) Normal 77 (87) 78 (80) 68 (73) 73 (76) 296 (79) Impaired 10 (11) 19 (19) 24 (26) 23 (24) 76 (20) Single glucose value 126 mg/dL (7.”
Evolution of pharmacological obesity treatments: focus on adverse side‐effect profiles
Krentz, A. J., Fujioka, K., & Hompesch, M. (2016) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12657 · Cited by 168
“LDL cholesterol, fasting plasma glucose, and systolic and diastolic blood pressure [106].”
Azlan, A., Sultana, S., Huei, C. S., & Razman, M. R. (2022) · Molecules · doi:10.3390/molecules27030898 · Cited by 164
“PUFAs plays a central role in suppressing lipogenesis and regulating adipocyte differentiation through suppression of late-phase adipocyte differentiation [61,62] Numerous natural products have apoptotic effects on maturing pre-adipocytes, such as capsaicin, linoleic acids, resveratrol, genistein, conjugated, and quer…”
BackgroundCalorie restriction mimetics: Can you have your cake and eat it, too?
Ingram, D. K., & Roth, G. S. (2015) · Ageing Research Reviews · doi:10.1016/j.arr.2014.11.005 · Cited by 161
Nikolic, D., Katsiki, N., Montalto, G., Isenovic, E., Mikhailidis, D., & Rizzo, M. (2013) · Nutrients · doi:10.3390/nu5030928 · Cited by 159
“any similar drugs on cardiovascular risk factors, if they are marketed [81].”
BackgroundSchwingshackl, L., Dias, S., & Hoffmann, G. (2014) · Systematic Reviews · doi:10.1186/2046-4053-3-130 · Cited by 131
“Furthermore anti-obesity drugs were associated with increased risk of total adverse events, tachycardia, gastrointestinal disease, hypertension and mouth dryness [58].”
BackgroundSahebkar, A., Simental‐Mendía, L. E., Reiner, Ž., Kovanen, P. T., Simental-Mendía, M. A., Bianconi, V., & Pirro, M. (2017) · Pharmacological Research · doi:10.1016/j.phrs.2017.05.022 · Cited by 127
Pipek, L. Z., Moraes, W. A. F., Nobetani, R. M., Cortez, V. S., Condi, A. S., Taba, J. V., Nascimento, R. F. V., Suzuki, M. O., do Nascimento, F. S., de Mattos, V. C., et al. (2024) · Scientific Reports · doi:10.1038/s41598-024-57724-5 · Cited by 80
“Finally, choosing the most appropriate treatment often involves individual characteristics of each patient, and the impact on quality of life can be extremely subjective and difficult to assess.”
BackgroundAntiobesity and Antioxidant Potentials of Selected Palestinian Medicinal Plants
Jamous, R. M., Abu-Zaitoun, S. Y., Akkawi, R. J., & Ali-Shtayeh, M. S. (2018) · Evidence-based Complementary and Alternative Medicine · doi:10.1155/2018/8426752 · Cited by 82
“That is the reason for the withdrawal from the market of some older drugs such as Sibutral, rimonabant, isomeride, ponderal, and Xenical [16, 18].”
BackgroundAlamuddin, N., Bakizada, Z. M., & Wadden, T. A. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.66.8806 · Cited by 74
New options for the treatment of obesity and type 2 diabetes mellitus (narrative review)
Henry, R. R., Chilton, R., & Garvey, W. T. (2013) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2013.04.011 · Cited by 53
“…prospective study, of 3305 obese patients • Randomized to lifestyle changes plus either orlistat 120 mg or PBO, TID • ITT-LOCF Mean weight loss at 4 years • Orlistat: 5.8 kg (P < .001 vs PBO) • PBO: 3.0 kg (Zhou et al., 2012) • Systematic review and meta-analysis to assess cardiometabolic…”
BackgroundInfluentialBenefit-Risk Assessment of Orlistat in the Treatment of Obesity
Sumithran, P., & Proietto, J. (2014) · Drug Safety · doi:10.1007/s40264-014-0210-7 · Cited by 63
“5 mmHg, respectively, than those taking placebo [37, 38].”
BackgroundInfluentialParé, D., Hilou, A., Ouédraogo, N., & Guenné, S. (2016) · Medicines · doi:10.3390/medicines3020009 · Cited by 52
“That is the reason for the withdrawal from the market of some older drugs such as Sibutral, Rimonabant, Isomeride, Ponderal and Xenical [5,6].”
BackgroundSheu, W. H., Chan, S. P., Matawaran, B. J., Deerochanawong, C., Mithal, A., Chan, J. C. N., Suastika, K., Khoo, C. M., Nguyen, H. M., Ji, L., et al. (2020) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2019.0208 · Cited by 57
Loves, S., de Jong, J., van Sorge, A., Telting, D., Tack, C. J., Hermus, A., Westerterp, K., & de Boer, H. (2013) · European Journal of Endocrinology · doi:10.1530/eje-13-0190 · Cited by 45
Karimi, G., Jamaluddin, R., Mohtarrudin, N., Ahmad, Z., Khaza’ai, H., & Parvaneh, M. (2017) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2017.06.020 · Cited by 48
Pharmacological Treatment for Obesity in Adults: An Umbrella Review
Khalil, H., Ellwood, L., Lord, H., & Fernandez, R. (2020) · Annals of Pharmacotherapy · doi:10.1177/1060028019898912 · Cited by 44
Tu, Y., Pan, Y., Han, J., Pan, J., Zhang, P., Jia, W., Bao, Y., & Yu, H. (2020) · International Journal of Obesity · doi:10.1038/s41366-020-00690-5 · Cited by 43
Cardiovascular disease prevention strategies for type 2 diabetes mellitus
Katsiki, N., Purrello, F., Tsioufis, C., & Mikhailidis, D. P. (2017) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2017.1351946 · Cited by 42
“Orlistat, lorcaserin and phentermine-topiramate have been reported to improve glycaemic control, BP and dyslipidaemia, whereas naltrexone-bupropion can beneficially affect glucose and lipid parameters [62-64].”
BackgroundArdissino, M., Vincent, M., Hines, O., Amin, R., Eichhorn, C., Tang, A. R., Collins, P., Moussa, O., & Purkayastha, S. (2022) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvaa133 · Cited by 40
Dedov, I. I., Melnichenko, G. A., Troshina, E. A., Mazurina, N. V., & Galieva, M. O. (2018) · Obesity Facts · doi:10.1159/000488880 · Cited by 40
Pharmacotherapy of Obesity: Limits and Perspectives
Rosa-Gonçalves, P., & Majerowicz, D. (2019) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-019-00328-6 · Cited by 34
Obesity an overview: Genetic conditions and recent developments in therapeutic interventions
Rao, V., Candasamy, M., & Bhattamisra, S. K. (2019) · Diabetes & Metabolic Syndrome Clinical Research & Reviews · doi:10.1016/j.dsx.2019.05.004 · Cited by 39
Del Re, A. C., Frayne, S. M., & Harris, A. H. S. (2014) · Obesity · doi:10.1002/oby.20810 · Cited by 31
“Several studies and meta-analyses have found orlistat to be modestly effective for reducing obesity, blood pressure, and onset of type 2 diabetes, and have found it to have a favorable benefit/risk profile (16-18).”
BackgroundMethodThe cardiovascular effects of novel weight loss therapies
Usman, M., Davies, M. J., Hall, M. E., Verma, S., Anker, S. D., Rosenstock, J., & Butler, J. (2023) · European Heart Journal · doi:10.1093/eurheartj/ehad664 · Cited by 31
Cai, M., & Zou, Z. (2015) · Obesity Research & Clinical Practice · doi:10.1016/j.orcp.2015.10.010 · Cited by 33
Management of obesity and cardiometabolic risk – role of phentermine/extended release topiramate
Caterson, I. D., Sweeting, A., Tabet, E. J., & Markovic, T. (2014) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s38979 · Cited by 36
Epidemiology of Obesity and Pharmacologic Treatment Options
Shettar, V., Patel, S., & Kidambi, S. (2017) · Nutrition in Clinical Practice · doi:10.1177/0884533617713189 · Cited by 26
Borges, C. D. S., Missassi, G., Pacini, E. S. A., Kiguti, L. R. D. A., Sanabria, M., da Silva, R. F., Banzato, T. P., Perobelli, J. E., Pupo, A. S., & Kempinas, W. D. G. (2013) · PLoS ONE · doi:10.1371/journal.pone.0066091 · Cited by 24
“Sibutramine, an appetite suppressant administered orally for obesity treatment [13], acts on the central nervous system as a”
BackgroundAntioxidant and anti-obesity properties of local chilies varieties in Malaysia
Huei, C. S., Azlan, A., Ismail, A., Shafie, N. H., & Sultana, S. (2020) · Journal of Food Science and Technology · doi:10.1007/s13197-020-04400-x · Cited by 25
“As for anti-obesity drugs, they can be categorized into three main actions, inhibit intestinal fat absorption, suppress appetite, and increase energy consumption or thermogenesis (Zhou et al. 2012).”
BackgroundSánchez-Cordero, S., de Gordejuela, A. G. R., Vilallonga, R., González, Ó., Ciscar, A., Ciudin, A., Zabalegui, A., & Armengol, M. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm12010187 · Cited by 24
“suggested that a total weight loss (%TWL) > 20% in the first year after surgery indicated a “good responder” [17] and was associated with a reduction in cardiovascular risk factors after weight loss (WL) of 5–10% regardless of the type of the medication taken [18].”
BackgroundBariatric Endocrinology: Principles of Medical Practice
González-Campoy, J. M., Richardson, B., Richardson, C., Gonzalez-Cameron, D., Ebrahim, A., Strobel, P., Martinez, T., Blaha, B., Ransom, M., Quinonez-Weislow, J., et al. (2014) · International Journal of Endocrinology · doi:10.1155/2014/917813 · Cited by 16
Luca, M. D., Belluzzi, A., Salminen, P. T. P., Bueter, M., Pujol‐Rafols, J., Sakran, N., Stier, C. K., Taşkın, H. E., Chiappetta, S., Carrano, F. M., et al. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13175106 · Cited by 17
“There are many studies and meta-analyses assessing the (short/medium-term) efficacy of pharmacological treatments in reducing body weight and some obesity-related medical conditions [31].”
BackgroundFarah, D., & Fonseca, M. C. M. (2019) · Clinical Therapeutics · doi:10.1016/j.clinthera.2019.06.005 · Cited by 11
Liao, Y.-N., Chen, H.-Y., Yang, C.-W., Lee, P.-W., Hsu, C.-Y., Huang, Y.-T., & Yang, T.-H. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.978814 · Cited by 7
“The complexity of conditions in patients with more comorbidities may lead to less body weight loss in participants with metabolic syndrome than in those without such comorbidities (Zhou et al., 2012).”
BackgroundWickramasinghe, M., & Weaver, J. U. (2017) · Elsevier eBooks · doi:10.1016/b978-0-323-48559-3.00010-5 · Cited by 10
The weight reduction mediated by anti-obesity medication and the cardiovascular outcome
Guo, Y., Chu, L., Cai, X., Wu, H., Yan, J., Li, Z., Jiao, R., Bai, S., Yang, W., Lv, F., et al. (2024) · iScience · doi:10.1016/j.isci.2024.110867 · Cited by 6
“35 The use of orlistat, naltrexone/bupro-pion and phentermine/topiramate also contributed to the improvement of cardiometabolic indicators, such as blood pressure, lipid profiles, fasting glucose and waist circumference.”
Kuo, H., Wang, K., Lee, Y., Lin, P., Liu, M., Lin, C., & Liu, L. Y. (2019) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1111/jcpt.13047 · Cited by 6
Fierro Rodríguez, D. (2025) · Revista de Derecho Civil · Cited by 6
Xie, P., Shao, T., Long, Y., Xie, W., Liu, Y., Yang, Y., Huang, Y., Wu, R., Deng, Q., & Tang, H. (2024) · Lipids in Health and Disease · doi:10.1186/s12944-024-02214-w · Cited by 8
“The results indicate that orlistat contributes to weight control and blood lipid homeostasis in antipsychotic-treated people, which is consistent with previous studies conducted in obese people [25–31, 47, 48].”
ResultAbnehmen beginnt im Kopf, nicht im Bauch
Gräf, C., Ferrari, N., & Eiser, S. (2013) · MMW - Fortschritte der Medizin · doi:10.1007/s15006-013-0327-0 · Cited by 5
Nutrition, Exercise, and Pharmaceutical Therapies for Sarcopenic Obesity
Wakabayashi, H., & Sakuma, K. (2013) · Journal of Nutritional Therapeutics · doi:10.6000/1929-5634.2013.02.02.5 · Cited by 7
Extrapolation from Clinical Trial to Practice: Current Pharmacotherapy on Obesity
Gorain, B., Choudhury, H., Sengupta, P., Verma, R. K., & Pandey, M. (2021) · Springer eBooks · doi:10.1007/978-981-33-6408-0_10 · Cited by 4
Secondary Dyslipidemia In Obese Children - Is There Evidence For Pharmacological Treatment?
Tanaka, A. C. S. (2018) · Arquivos Brasileiros de Cardiologia · doi:10.5935/abc.20180187 · Cited by 4
Biotherapeutic approaches against cardio-metabolic dysfunctions based on extracellular vesicles
Marchal, S., Andriantsitohaina, R., & Martínez, M. C. (2024) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2024.167095 · Cited by 3
Rosa, F., Négrier, P., & Espeau, P. (2016) · CrystEngComm · doi:10.1039/c6ce01123c · Cited by 3
Effect of Aphanizomenon flos-aquae (AFA) or Orlistat on hyperlipidemic adult male Albino rats
Zahkouk, S. A., Eid, F. A., Abdelhafez, H., & El-Wahsh, A. M. S. E.-D. A. (2019) · Journal of Medical and Life Science · doi:10.21608/jmals.2019.131766 · Cited by 3
“Results of the present study are in agreement with those described by Zhou et al. (2012) who stated that orlistat 120 mg treatment reduced body weight and improved cardiovascular risk factors, including a decrease in total and LDL cholesterol, fasting plasma glucose, and systolic and diastolic…”
ResultTkachenko, V. I., & Bagro, T. (2023) · Family Medicine & Primary Care Review · doi:10.5114/fmpcr.2023.132617 · Cited by 2
KAÇMAZ, M., Trawally, M., & Güzel-Akdemir, Ö. (2024) · Journal of Research in Pharmacy · doi:10.29228/jrp.735 · Cited by 3
“However, some potential side effects include, but not limited to, cardiotoxicity, have been reported, causing a restriction on its usage [11].”
3 Medical Management of Obesity
Burguera, B. G., & Tur, J. (2014) · Springer eBooks · doi:10.1007/978-1-4939-1637-5_3 · Cited by 2
Almestrand, S., Wang, X., Jeppsson-Ahlberg, Å., Nordgren, M., Flygare, J., Christensson, B., Rössner, S., & Sander, B. (2015) · PeerJ · doi:10.7717/peerj.1056 · Cited by 2
“Hence the drug was withdrawn from clinical use but there 58 is remaining interest in some of its many potential medical applications (Cooper & Regnell 2014; 59 Zhou et al. 2012) including treatment of various malignancies.”
BackgroundORLISTAT IN COMBINATION THERAPY OF OBESITY AND TYPE 2 DIABETES
Mkrtumyan, A. M., & Biryukova, E. V. (2017) · Meditsinskiy sovet = Medical Council · doi:10.21518/2079-701x-2017-3-68-74 · Cited by 2
The Impact of Obesity on Thoracic and Cardiac Surgery
Gerosa, G., Schiavon, M., Marulli, G., Tarzia, V., & Rea, F. (2014) · Springer eBooks · doi:10.1007/978-88-470-5382-3_8 · Cited by 1
Sibutramine and Rimonabant: A Postmortem Forensic Examination
Wittert, G. (2013) · Springer eBooks · doi:10.1007/978-1-4471-2834-2_28 · Cited by 1
Dyslipidemia and Cardiovascular Risk in Obesity
Arca, M. (2014) · Springer eBooks · doi:10.1007/978-3-319-09045-0_12 · Cited by 2
Mete, R., Georgousopoulou, E. N., Mellor, D. D., Khoo, J. J. C., Cheong, M., Leeds, A., Allan, K., Avery, A., Hart, K., Muir, A., et al. (2017) · Wiley eBooks · doi:10.1002/9781118857991.ch4 · Cited by 2
Stress, Affect Systems and Eating Pathology in Problematic Weight Regulation
Kupeli, N. (2014) · University of Hertfordshire Research Archive (University of Hertfordshire) · doi:10.18745/th.15438 · Cited by 2
Abnehmen beginnt im Kopf, nicht im Bauch
Gräf, C., Ferrari, N., & Eiser, S. (2013) · Uro-News · doi:10.1007/s00092-013-0177-1
Rodríguez-Valle, A., Ferrando, M. Á. N., Carceller, D. B., González-Cantalejo, M., Marcén, J. F. E., & Sanz‐París, A. (2016) · Nutrición Hospitalaria · doi:10.20960/nh.525 · Cited by 1
“However, the direct effect of anti-obesity drugs on cardiovascular risk factors is unclear (13).”
BackgroundOverview of Medical and Surgical Treatment of Severe Obesity
Prabhu, K. L., & Jackson, T. D. (2016) · Springer eBooks · doi:10.1007/978-3-319-42536-8_6
ANALES DE LA REAL ACADEMIA NACIONAL DE FARMACIA
Tamargo, J. L. (2016)
Medically Supervised Weight Loss Programs
Corcelles, R., & Burguera, B. G. (2018) · Springer eBooks · doi:10.1007/978-3-319-71282-6_20 · Cited by 1
Optimizing individual heart failure treatment
Agewall, S. (2021) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvab087 · Cited by 2
Oroko, M., Llano, A., & Fisher, M. (2022) · Wiley eBooks · doi:10.1002/9781119785033.ch13
The inhibitory effect of anthocyanins-rich Thai berries extracts on lipid digestion and absorption
Chamnansilpa, N. (2017) · Chula Digiverse · doi:10.58837/chula.the.2017.255
Hasan, N. A., Kalanjati, V. P., Purwantari, K. E., Abdurachman, A., & Miftahussurur, M. (2023) · Journal of Pharmacy & Pharmacognosy Research · doi:10.56499/jppres23.1741_12.2.218 · Cited by 1
Сучасні підходи до комплексного лікування ожиріння з пацієнторієнтованим підходом
Tkachenko, V. I., & Bagro, T. (2023) · Health of Society · doi:10.22141/2306-2436.12.2.2023.305 · Cited by 1
Weight Loss Speed and Early Predictors to Success After Bariatric Surgery
Sánchez-Cordero, S., Vilallonga, R., de Gordejuela, A. G. R., Ciudin, A., & Armengol, M. (2024) · Bariatric Surgical Practice and Patient Care · doi:10.1089/bari.2023.0064
“18 Despite signi fi cant weight loss after BS, there is a sub-group of patients who fail to achieve successful weight loss or experience long-term weight regain.”
Aamir, A. B., Latif, R., Fallatah, J. O., Alqoofi, J. F., Alsalman, H. A., & Almarzoq, F. A. (2025) · International Journal of Adolescent Medicine and Health · doi:10.1515/ijamh-2024-0196 · Cited by 1
Xie, P., Shao, T., Long, Y., Xie, W., Liu, Y., Yang, Y., Huang, Y., Wu, R., Deng, Q., & Tang, H. (2024) · Figshare · doi:10.6084/m9.figshare.26367930
Metadata
- Authors
- Zhou, Y.-H., Ma, X.-Q., Wu, C., Lu, J., Zhang, S.-S., Guo, J., Wu, S.-Q., Ye, X.-F., Xu, J.-F., & He, J.
- Affiliations
- Second Military Medical University (CN)
- Corresponding author
- He, Jia
- Venue
- PLoS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2012-06-20
- Volume
- 7
- Issue
- 6
- Pages
- e39062
- ISSN
- 1932-6203 (ISSN-L)
- PMC
- PMC3380040
- OpenAlex
- W2163687543
- Cited by
- 84
- References
- 57
- Citations by year
- 2025: 2 · 2024: 8 · 2023: 4 · 2022: 4 · 2021: 3 · 2020: 5 · 2019: 6 · 2018: 5 · 2017: 8 · 2016: 8 · 2015: 8 · 2014: 10 · 2013: 13
- FWCI
- 1.15
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- PLoS ONE (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Figshare (submittedVersion, cc-by)
- Funders
- National Natural Science Foundation of China
- Program of Shanghai Subject Chief Scientist
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Blood Pressure and Hypertension Studies
- Health Sciences › Medicine › Surgery › Bariatric Surgery and Outcomes
- Keywords
- anti-obesity drugs, cardiovascular risk factors, orlistat, sibutramine, rimonabant, weight loss, blood pressure, cholesterol, triglycerides, fasting blood glucose, obesity
- MeSH terms
- Cardiovascular Diseases, Humans, Obesity, Weight Loss, Randomized Controlled Trials as Topic, Anti-Obesity Agents
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.